<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647189</url>
  </required_header>
  <id_info>
    <org_study_id>DIVA-001</org_study_id>
    <nct_id>NCT03647189</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Trial With Hybrid Fractional Laser</brief_title>
  <official_title>Randomized, Controlled Trial With Hybrid Fractional Laser for Vulvovaginal Atrophy in Breast Cancer Survivors and Menopausal Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciton</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sciton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, controlled trial will evaluate hybrid fractional laser treatment for
      vulvovaginal atrophy in breast cancer survivors and menopausal females
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Vaginal health index score (VHIS)</measure>
    <time_frame>6 months</time_frame>
    <description>Scores vaginal health by scoring it from 1(none) - 5(excellent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Female sexual function index questionnaire (FSFI)</measure>
    <time_frame>6 months</time_frame>
    <description>Scoring 0(minimum) - 5(maximum)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in day-to-day impact of vaginal aging questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in histology</measure>
    <time_frame>3 months</time_frame>
    <description>Histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in photography</measure>
    <time_frame>6 months</time_frame>
    <description>Photography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with hybrid fractional laser</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hybrid Fractional Laser</intervention_name>
    <description>Hybrid Fractional Laser</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Healthy biological female aged between 40 to 70 years 2. Is post-menopausal with a
             AND b OR c:

               1. No menses for at least 12 months

               2. Follicle-stimulating hormone (FSH) level over 40mlU/mL

               3. Has had a bilateral oophorectomy at least 12 months ago with no hormone
                  replacement 3. Is experiencing at least two self-reported symptoms of GSM, such
                  as

               1. Vaginal irritation in the absence of infection

               2. Chronic burning sensation

               3. Chronic itching in the absence of infection

               4. Recurring urinary tract infections (UTIs)

               5. Vaginal dryness during sexual activity

               6. Pain during sexual activity (dyspareunia) 4. Has been experiencing symptoms of
                  GSM for greater than 3 months 5. Is unable due to a medical contraindication or
                  unwilling to receive hormone-based vaginal therapy 6. Early menopause after
                  breast cancer 7. Normal and up to date pap smear, if applicable 8. Is sexually
                  active (i.e. intravaginal intercourse) or has the potential and desire to be
                  sexually active if symptoms of GSM improve 9. Can read, understand and sign
                  informed consent form 10. Has indicated willingness to participate in the study
                  by signing an informed consent form 11. Agrees to adhere to the treatment and
                  follow-up schedule and post treatment care instructions

        Exclusion Criteria:

          -  1. Undiagnosed abnormal genital bleeding 2. Has history of pelvic surgery or other
             energy-based vaginal therapy within 12 months prior to enrollment 3. Previous use of
             topical estrogen therapy within the last 6 months 4. Has used vaginal creams,
             moisturizers, lubricants or homeopathic preparations, or received anticoagulants,
             antiplatelet, thrombolytic, vitamin E or anti-inflammatory within 2 weeks of treatment
             5. Has history of heart failure 6. Has equal to or greater than stage III prolapse,
             according to pelvic organ prolapse quantification system (POP-Q) 7. Has an active
             sexually transmitted infection (STI) 8. Has signs or symptoms of vulvitis/vaginitis 9.
             Has signs or symptoms of acute urinary tract infection (UTI) 10. Has participated in
             any clinical trial involving an investigational drug or procedure within past 30 days
             11. The investigator feels that for any reason the subject is not eligible to
             participate in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sciton Inc</last_name>
    <phone>6504939155</phone>
    <email>jay.patel@sciton.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miamim Dermatology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspareunia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

